What is OBX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.80B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OBX?

P/E (TTM) is n/a and 52-week range is $12.07 to $49.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OBX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Obsidian Therapeutics, Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bedford, Massachusetts, US, ISIN US67448A1060 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Obsidian Therapeutics Inc. engages in developing cell and gene therapies, particularly for the treatment of solid tumors and cancer. The company is headquartered in Bedford, Massachusetts and currently employs 3 full-time employees. Its proprietary cytoDRiVE technology is designed to regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Its lead clinical program, OBX-115, is an investigational TIL cell therapy engineered to express membrane-bound IL15 (mbIL15), which is designed to support TIL activity. Its cytoDRiVE discovery platform has identified a library of internally discovered drug-responsive domains (DRDs) of varying sizes and intended purposes and enables rapid optimization of regulatable and functional proteins in any cell type. The company has developed a synthetic biology engineering toolkit that supports the design and optimization of a range of therapeutic proteins, including but not limited to type I/II membrane proteins, and membrane-bound cytokines.

Employees

Website

obsidiantx.com

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)